Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. (7th August 2019)

• Record Type: Journal Article
• Authors: Willmann, Stefan; Frei, Matthias; Sutter, Gabriele; Coboeken, Katrin; Wendl, Thomas; Eissing, Thomas; Lippert, Jörg; Stass, Heino
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 8:Number 9(2019)
• Page Start: 654
• Page End: 663
• Publication Date: 2019-08-07
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12446
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract : Moxifloxacin is a widely used fluoroquinolone for the treatment of complicated intra‐abdominal infections. We applied physiologically‐based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling to support dose selection in pediatric patients. We scaled an existing adult PBPK model to children based on prior physiological knowledge. The resulting model proposed an age‐dependent dosing regimen that was tested in a phase I study. Refined doses were then tested in a phase III study. A popPK analysis of all clinical pediatric data confirmed the PBPK predictions, including the proposed dosing schedule in children, and supported pharmacokinetics‐related safety/efficacy questions. The pediatric PBPK model adequately predicted the doses necessary to achieve antimicrobial efficacy while maintaining safety in the phase I and III pediatric studies. Altogether, this study retroactively demonstrated the robustness and utility of modeling to support dose finding and confirmation in pediatric drug development for moxifloxacin.